These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35181572)

  • 1. Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial.
    Dellon ES; Lucendo AJ; Schlag C; Schoepfer AM; Falk GW; Eagle G; Nezamis J; Comer GM; Knoop K; Hirano I
    Clin Gastroenterol Hepatol; 2022 Nov; 20(11):2485-2494.e15. PubMed ID: 35181572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis.
    Hirano I; Safroneeva E; Roumet MC; Comer GM; Eagle G; Schoepfer A; Falk GW
    Aliment Pharmacol Ther; 2020 Apr; 51(8):750-759. PubMed ID: 32149424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Budesonide vs Fluticasone for Initial Treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial.
    Dellon ES; Woosley JT; Arrington A; McGee SJ; Covington J; Moist SE; Gebhart JH; Tylicki AE; Shoyoye SO; Martin CF; Galanko JA; Baron JA; Shaheen NJ
    Gastroenterology; 2019 Jul; 157(1):65-73.e5. PubMed ID: 30872104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Swallowed Fluticasone Propionate Is an Effective Long-Term Maintenance Therapy for Children With Eosinophilic Esophagitis.
    Andreae DA; Hanna MG; Magid MS; Malerba S; Andreae MH; Bagiella E; Chehade M
    Am J Gastroenterol; 2016 Aug; 111(8):1187-97. PubMed ID: 27325220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.
    Hirano I; Dellon ES; Hamilton JD; Collins MH; Peterson K; Chehade M; Schoepfer AM; Safroneeva E; Rothenberg ME; Falk GW; Assouline-Dayan Y; Zhao Q; Chen Z; Swanson BN; Pirozzi G; Mannent L; Graham NMH; Akinlade B; Stahl N; Yancopoulos GD; Radin A
    Gastroenterology; 2020 Jan; 158(1):111-122.e10. PubMed ID: 31593702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial.
    Lucendo AJ; Miehlke S; Schlag C; Vieth M; von Arnim U; Molina-Infante J; Hartmann D; Bredenoord AJ; Ciriza de Los Rios C; Schubert S; Brückner S; Madisch A; Hayat J; Tack J; Attwood S; Mueller R; Greinwald R; Schoepfer A; Straumann A;
    Gastroenterology; 2019 Jul; 157(1):74-86.e15. PubMed ID: 30922997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results from a Phase 3 Trial.
    Hirano I; Collins MH; Katzka DA; Mukkada VA; Falk GW; Morey R; Desai NK; Lan L; Williams J; Dellon ES;
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):525-534.e10. PubMed ID: 33887475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis.
    Dellon ES; Katzka DA; Collins MH; Hamdani M; Gupta SK; Hirano I;
    Gastroenterology; 2017 Mar; 152(4):776-786.e5. PubMed ID: 27889574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Food Intake and Body Position on the Pharmacokinetics of Swallowed APT-1011, a Fluticasone Orally Disintegrating Tablet, in Healthy Adult Volunteers.
    Comer GM; Bush MA; Dellon ES; Marino MT
    J Clin Pharmacol; 2020 Jun; 60(6):734-743. PubMed ID: 31943257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pooled Phase 2 and 3 Efficacy and Safety Data on Budesonide Oral Suspension in Adolescents with Eosinophilic Esophagitis.
    Mukkada VA; Gupta SK; Gold BD; Dellon ES; Collins MH; Katzka DA; Falk GW; Williams J; Zhang W; Boules M; Hirano I; Desai NK
    J Pediatr Gastroenterol Nutr; 2023 Dec; 77(6):760-768. PubMed ID: 37718471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis.
    Alexander JA; Jung KW; Arora AS; Enders F; Katzka DA; Kephardt GM; Kita H; Kryzer LA; Romero Y; Smyrk TC; Talley NJ
    Clin Gastroenterol Hepatol; 2012 Jul; 10(7):742-749.e1. PubMed ID: 22475741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.
    Hirano I; Collins MH; Assouline-Dayan Y; Evans L; Gupta S; Schoepfer AM; Straumann A; Safroneeva E; Grimm M; Smith H; Tompkins CA; Woo A; Peach R; Frohna P; Gujrathi S; Penenberg DN; Li C; Opiteck GJ; Olson A; Aranda R; Rothenberg ME; Dellon ES;
    Gastroenterology; 2019 Feb; 156(3):592-603.e10. PubMed ID: 30395812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variation in Endoscopic Activity Assessment and Endoscopy Score Validation in Adults With Eosinophilic Esophagitis.
    Schoepfer AM; Hirano I; Coslovsky M; Roumet MC; Zwahlen M; Kuehni CE; Hafner D; Alexander JA; Dellon ES; Gonsalves N; Leung J; Bussmann C; Collins MH; Newbury RO; Smyrk TC; Woosley JT; Yang GY; Romero Y; Katzka DA; Furuta GT; Gupta SK; Aceves SS; Chehade M; Spergel JM; Falk GW; Meltzer BA; Comer GM; Straumann A; Safroneeva E;
    Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1477-1488.e10. PubMed ID: 30476587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budesonide Oral Suspension Significantly Improves Eosinophilic Esophagitis Histology Scoring System Results: Analyses From a 12-Week, Phase 2, Randomized, Placebo-controlled Trial.
    Collins MH; Dellon ES; Katzka DA; Hirano I; Williams J; Lan L
    Am J Surg Pathol; 2019 Nov; 43(11):1501-1509. PubMed ID: 31498177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis.
    Straumann A; Lucendo AJ; Miehlke S; Vieth M; Schlag C; Biedermann L; Vaquero CS; Ciriza de Los Rios C; Schmoecker C; Madisch A; Hruz P; Hayat J; von Arnim U; Bredenoord AJ; Schubert S; Mueller R; Greinwald R; Schoepfer A; Attwood S;
    Gastroenterology; 2020 Nov; 159(5):1672-1685.e5. PubMed ID: 32721437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvements in Dysphagia and Pain With Swallowing in Patients With Eosinophilic Esophagitis Receiving Budesonide Oral Suspension.
    Dellon ES; Collins MH; Katzka DA; Hudgens S; Lan L; Williams J; Vera-Llonch M; Hirano I
    Clin Gastroenterol Hepatol; 2021 Apr; 19(4):699-706.e4. PubMed ID: 32272243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis.
    Butz BK; Wen T; Gleich GJ; Furuta GT; Spergel J; King E; Kramer RE; Collins MH; Stucke E; Mangeot C; Jackson WD; O'Gorman M; Abonia JP; Pentiuk S; Putnam PE; Rothenberg ME
    Gastroenterology; 2014 Aug; 147(2):324-33.e5. PubMed ID: 24768678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel corticosteroid formulations in the treatment of eosinophilic esophagitis: what is the evidence?
    Walgraeve S; Vanuytsel T
    Acta Gastroenterol Belg; 2023; 86(3):437-448. PubMed ID: 37814560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma.
    ZuWallack R; Adelglass J; Clifford DP; Duke SP; Wire PD; Faris M; Harding SM
    Chest; 2000 Aug; 118(2):303-12. PubMed ID: 10936117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective Comparison of Fluticasone Propionate and Oral Viscous Budesonide in Children With Eosinophilic Esophagitis.
    Fable JM; Fernandez M; Goodine S; Lerer T; Sayej WN
    J Pediatr Gastroenterol Nutr; 2018 Jan; 66(1):26-32. PubMed ID: 28489670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.